Regeneron received accelerated approval from the U.S. Food and Drug Administration for its gene therapy Otarmeni (lunsotogene parvec‑cwha) on April 23 2026. The therapy is the first in‑vivo gene treatment approved for OTOF‑related severe‑to‑profound sensorineural hearing loss, a rare genetic condition that affects roughly 50 newborns each year in the United States.
The approval was based on the CHORD Phase 1/2 study, in which 80 % of participants achieved the primary endpoint of improved hearing sensitivity and 42 % reached normal hearing levels after longer follow‑up. The durable hearing improvement was achieved by delivering a functional copy of the OTOF gene directly into the cochlea via an adeno‑associated virus vector, restoring auditory nerve signaling.
Otarmeni’s approval marks Regeneron’s first entry into the gene‑therapy market and expands its portfolio into a new therapeutic area with a clear unmet need. The company has committed to providing the therapy free of charge in the United States, a strategy aimed at accelerating patient access and establishing a precedent for future gene‑therapy launches.
The therapy was approved under the FDA Commissioner’s National Priority Voucher program, which shortens review times for treatments that address large unmet medical needs. Regeneron was among the first nine companies to receive a voucher in October 2025, underscoring the program’s role in expediting breakthrough therapies.
Eli Lilly is developing a similar otoferlin‑targeted gene therapy (AK‑OTOF), indicating that a competitive landscape is emerging for this rare‑disease indication.
Regeneron’s recent financial performance provides context for the significance of the approval. In Q4 2025 the company reported total revenues of $3.9 billion, a 3 % year‑over‑year increase driven by strong sales of Dupixent, EYLEA HD, and Libtayo, while R&D expenses rose to $1.3 billion as the company invested heavily in late‑stage programs. In Q1 2025 revenues were $3.0 billion and R&D expenses were $1.2 billion, reflecting a continued focus on pipeline development.
Management highlighted the strategic importance of Otarmeni. Senior vice president Aris Baras described the therapy as “really our first foray” into genetic medicine, while vice president Jonathon Whitton emphasized the emotional impact of hearing restoration for patients.
Regeneron’s stock traded in the range of $760.99 to $766.13 on the day of the approval. The market reaction was driven by the company’s recent earnings beat, the strategic significance of entering the gene‑therapy space, and analysts’ continued confidence in Regeneron's pipeline and commercial performance.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.